A bag used for IV transfusions in healthcare contexts. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Recce Pharma (ASX:RCE) has announced the latest cohort of patients part of the company’s Phase I/II UTI trial has been dosed with the highest ever volume of R327 to date.

In the ongoing IV-based trial that seeks to treat urinary tract infections, patients are now being injected with 4,000mg of the company’s flagship anti-infective.

The company has been testing the dosages over varied timeframes ranging from 45 minutes down to 15 minutes. The company is heading for a position where it can dose patients as quickly and hassle-free as possible.

The stock, ultimately, wants to treat UTIs with a one-time-only dose of R327 in sub-15 minute timeframes.

The company reported on Wednesday that its Minimum Inhibitory Concentration (MIC) activity against bacteria has already been identified based on existing clinical data.

At the wrap-up of the trial, the company will be able to release data surrounding the full efficacy of R327.

RCE last traded at 61.5cps.

RCE by the numbers
More From The Market Online

Canberra greenlights Maximus for Korean firm’s 30% farm-in at Lefroy

Maximus Resources has received approval from Canberra for a Korean mining firm to farm-in for 30%…

Telix Pharma gears up to launch US IPO

Telix Pharmaceuticals has announced it's working with Morgan Stanley to list depository shares on the NASDAQ.

Market Open: ASX200 set to rise as VIX hits 5-year-low

Good morning. It’s looking like a good start to the week on the futures market with…

Week 20 Wrap: EU-to-China cargoes up 12% YTD; US CPI tame

US inflation was the biggest data drop of the week; Anglo American is restructuring to fend…